Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer
- 1 October 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, S1-S7
- https://doi.org/10.1053/j.seminoncol.2006.08.002
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Human Pancreatic Carcinoma CellsCancer Research, 2006
- Improving delivery of antineoplastic agents with anti‐vascular endothelial growth factor therapyCancer, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- The Hallmarks of CancerCell, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971